List of Excipients in Branded Drug OXTELLAR XR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Supernus Pharmaceuticals Inc	OXTELLAR XR	oxcarbazepine	17772-121	CELLULOSE, MICROCRYSTALLINE
Supernus Pharmaceuticals Inc	OXTELLAR XR	oxcarbazepine	17772-121	FERRIC OXIDE YELLOW
Supernus Pharmaceuticals Inc	OXTELLAR XR	oxcarbazepine	17772-121	HYPROMELLOSE
Supernus Pharmaceuticals Inc	OXTELLAR XR	oxcarbazepine	17772-121	MAGNESIUM STEARATE
Supernus Pharmaceuticals Inc	OXTELLAR XR	oxcarbazepine	17772-121	METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER
Supernus Pharmaceuticals Inc	OXTELLAR XR	oxcarbazepine	17772-121	POLYETHYLENE GLYCOL 2000

Oxtellar XR Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Oxtellar XR is an extended-release oxcarbazepine tablet marketed by Supernus Pharmaceuticals for once-daily treatment of partial-onset seizures. Its commercial value is tied to controlled release of oxcarbazepine, tolerability, dosing convenience, and patent protection around the extended-release formulation rather than to the active ingredient, which is long genericized in immediate-release form.

The strongest excipient opportunities are controlled-release matrix optimization, tablet manufacturability, dose flexibility, coating performance, and differentiated generic or 505(b)(2) products. The principal commercial risk is that an excipient change can alter oxcarbazepine release, exposure to the active metabolite 10-monohydroxy derivative, or food-effect behavior, creating bioequivalence and intellectual-property challenges.

What is Oxtellar XR and how does its formulation work?

Oxtellar XR contains oxcarbazepine in 150 mg, 300 mg, and 600 mg extended-release tablets. The product is administered once daily and is approved as monotherapy or adjunctive therapy for partial-onset seizures in adults and pediatric patients six years of age and older.[1]

Oxcarbazepine is rapidly converted to its active metabolite, 10-monohydroxy derivative, commonly called MHD. Formulation performance must therefore control oxcarbazepine release over the dosing interval while maintaining clinically acceptable MHD exposure.

The product’s formulation objectives include:

• Sustained release over approximately 24 hours
• Reduced peak-related adverse effects compared with more frequent immediate-release dosing
• Once-daily administration
• Consistent tablet performance across the 150 mg, 300 mg, and 600 mg strengths
• Controlled food-effect behavior
• Adequate mechanical strength and storage stability

Oxtellar XR is a matrix-based oral solid dosage product using conventional pharmaceutical excipients combined with a proprietary extended-release design. The label identifies inactive ingredients that include hypromellose, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, talc, and titanium dioxide.[1]

What excipients are used in Oxtellar XR?

Excipient	Likely formulation role
Hypromellose	Hydrophilic release-controlling polymer and matrix former
Microcrystalline cellulose	Diluent, compressibility aid, and tablet structure
Crospovidone	Disintegration and internal water-management aid
Colloidal silicon dioxide	Glidant and powder-flow aid
Magnesium stearate	Lubricant
Polyvinyl alcohol	Film-coating polymer
Talc	Coating aid and anti-tacking agent
Titanium dioxide	Opacifier and colorant

The exact grade, particle-size distribution, substitution level, viscosity grade, granulation sequence, compression force, and coating parameters can materially affect dissolution. The public label identifies ingredients but does not disclose the complete critical formulation and process design.

What is the commercial role of Oxtellar XR’s excipient system?

The excipient system has commercial value because oxcarbazepine immediate-release products are widely available at low cost. A competing product must therefore provide either a lower-cost extended-release alternative or a clinically meaningful improvement in dosing, tolerability, adherence, or administration.

The main value drivers are:

1. Release control. Hypromellose concentration and viscosity can determine gel-layer formation and drug diffusion.
2. Dose scaling. The formulation must preserve release behavior across 150 mg, 300 mg, and 600 mg strengths.
3. Manufacturing robustness. A formulation that depends on narrow polymer hydration or compression conditions can create scale-up risk.
4. Bioequivalence. Release differences can change Cmax, AUC, Tmax, and MHD exposure.
5. Food-effect control. Modified-release oxcarbazepine products must be evaluated under fed and fasted conditions.
6. Patient adherence. Once-daily treatment creates a commercial distinction from immediate-release oxcarbazepine, which is commonly administered twice daily.
7. Substitution economics. A generic or follow-on product must compete against both branded Oxtellar XR and low-cost immediate-release oxcarbazepine.

What formulation strategies could compete with Oxtellar XR?

Hydrophilic matrix reformulation

The most direct strategy is a hydrophilic matrix using hypromellose or another swellable polymer. Commercial advantages include established manufacturing equipment, broad excipient supply, and familiar regulatory precedent.

Potential design variables include:

• Polymer viscosity grade
• Polymer loading
• Oxcarbazepine-to-polymer ratio
• Tablet hardness
• Granulation method
• Lubrication time
• Compression profile
• Tablet dimensions and surface-area-to-volume ratio

A matrix formulation can be commercially attractive, but a simple substitution of one polymer grade for another may not be sufficient. Release kinetics can change sharply with polymer hydration, tablet porosity, and agitation conditions.

Insoluble or swellable polymer combinations

A combination of hydrophilic and insoluble polymers could produce a more robust release profile. Examples include blending hypromellose with ethylcellulose or another water-insoluble barrier polymer.

This approach may help control burst release and reduce sensitivity to tablet hardness. It can also create additional process and regulatory complexity. A new polymer combination may require broader dissolution characterization and a more extensive in vitro-in vivo correlation program.

Multiparticulate or pellet-based products

A pellet or multiparticulate capsule could offer:

• Flexible release control
• Lower sensitivity to single-tablet mechanical defects
• Potential dose titration through capsule fill weight
• Potential use in patients who have difficulty swallowing tablets

The disadvantages are higher manufacturing cost, more complex encapsulation, and possible difficulty matching Oxtellar XR’s pharmacokinetic profile. A multiparticulate product would likely be a new dosage-form strategy rather than a straightforward generic tablet substitution.

Osmotic or membrane-controlled systems

An osmotic tablet or membrane-controlled system could provide strong control over oxcarbazepine release. It could also establish a differentiated patent position if the delivery mechanism is technically distinct.

The commercial barriers are significant:

• More complex manufacturing
• Greater coating-process sensitivity
• Higher equipment requirements
• More difficult scale-up
• Possible need for specialized dissolution methods
• Greater risk that the product is treated as a formulation innovation rather than a conventional generic

Sprinkle, dispersible, or pediatric dosage forms

A pediatric-friendly version could target children who cannot swallow extended-release tablets. Potential formats include multiparticulate capsules, sprinkle formulations, or orally dispersible systems.

The core technical problem is preserving extended release after administration with soft food or liquid. Immediate-release disruption of a modified-release system could create an inappropriate exposure profile. A successful product would need strong control over particle size, polymer coating, dose uniformity, and administration instructions.

What patents protect Oxtellar XR?

Protection for Oxtellar XR is primarily associated with the extended-release formulation, release profile, dosage form, and related manufacturing concepts. Oxcarbazepine itself is an older active pharmaceutical ingredient and does not provide meaningful composition-of-matter exclusivity for Oxtellar XR.

Orange Book status and regulatory exclusivity

Oxtellar XR was approved by the FDA in October 2012.[2] Because oxcarbazepine was not a new chemical entity, Oxtellar XR did not receive five-year NCE exclusivity. Any three-year exclusivity associated with new clinical investigations would have expired long before the current commercial period.

The product’s remaining protection therefore depends mainly on listed patents and associated litigation outcomes. Orange Book listings should be reviewed by product strength and patent number because listed patents, pediatric extensions, delisting events, and litigation outcomes can change over time.[3]

Protection category	Oxtellar XR relevance
NCE exclusivity	Not applicable to the old active ingredient
New dosage-form exclusivity	Historical period, expired
Pediatric exclusivity	Depends on FDA grant and applicable listed protection
Formulation patents	Core potential barrier
Method-of-use patents	May cover seizure treatment or dosing regimens
Manufacturing patents	May affect process-based follow-on strategies
Orange Book patents	Central to ANDA Paragraph IV timing
Regulatory exclusivity today	Patent-dependent rather than NCE-dependent

A commercial diligence review should distinguish patents that cover the approved product from patents that cover broader formulation concepts, specific release ranges, treatment methods, or manufacturing steps. A patent with broad claim language may be commercially important even if a generic applicant can design around one claim set.

When does Oxtellar XR lose exclusivity?

There is no single exclusivity date that captures all Oxtellar XR risk. Generic entry depends on:

• The expiration dates of currently listed Orange Book patents
• Any applicable pediatric extensions
• Paragraph IV certifications
• Litigation filing dates
• Thirty-month stays
• Settlement agreements
• Court findings on validity, enforceability, and infringement
• Whether a generic applicant can omit or carve out protected indications
• Whether a follow-on product uses a non-infringing release mechanism

FDA approval in 2012 means statutory regulatory exclusivity is no longer the primary barrier. The commercial entry window is instead determined by the surviving patent estate and any settlement-controlled launch date.

Which companies are challenging Oxtellar XR?

Generic oxcarbazepine manufacturers are the natural challengers because immediate-release oxcarbazepine is already widely marketed. Potential ANDA applicants include large generic companies with modified-release tablet capabilities and contract development organizations that can develop a bioequivalent product for a sponsor.

A Paragraph IV challenge would require an applicant to assert that listed Oxtellar XR patents are invalid, unenforceable, or not infringed. The applicant could also use a Paragraph III certification, wait for patent expiration, or pursue a formulation that avoids the listed claims.

The most important competitive distinction is between:

• A conventional ANDA targeting the same extended-release tablet
• A non-infringing extended-release formulation
• A 505(b)(2) product with a different dosage form, administration method, or clinical positioning
• An immediate-release product competing on price but not directly substituting for once-daily therapy

Without a current Orange Book and court-docket review, a definitive list of active Paragraph IV challengers and settlement terms cannot be established accurately.

What generic entry risks exist for Oxtellar XR?

At-risk launch

An at-risk launch could occur after a Paragraph IV certification but before final resolution of patent litigation. The commercial upside is substantial if the entrant captures price-sensitive prescriptions, but damages exposure and injunctive risk can be high.

Authorized generic or branded discounting

Supernus could respond to generic pressure through authorized-generic distribution, contracting, rebates, or price reductions. These measures could reduce the net sales opportunity for an independent generic.

Therapeutic substitution

Immediate-release oxcarbazepine is not a perfect substitute for Oxtellar XR because dosing frequency and pharmacokinetics differ. Nevertheless, payers may encourage conversion when the price gap is large.

Formulation failure

A generic that matches average exposure but has inferior dissolution robustness, food-effect behavior, or strength proportionality may face commercial and regulatory problems. Extended-release products are especially vulnerable to manufacturing changes after approval.

What formulation patents could support a new commercial product?

The strongest patent opportunities would focus on technical features that are difficult to design around and clinically relevant. Potential claim categories include:

• Specific polymer combinations
• Defined polymer viscosity ranges
• Release profiles at multiple dissolution pH levels
• Reduced food effect
• Dose-proportional extended release
• Multiparticulate delivery systems
• Pediatric sprinkle administration
• Abuse-deterrent or tamper-resistant designs, if technically relevant
• Manufacturing processes that produce a defined porosity or hardness range
• Correlation between in vitro release and MHD exposure
• Reduced peak concentration or improved tolerability

Method-of-use claims could target once-daily administration, conversion from immediate-release oxcarbazepine, pediatric dosing, or use in patients who experience peak-related adverse effects. Method claims are commercially useful but may be less effective against a generic that uses a label carve-out.

How strong is the Oxtellar XR patent estate?

The estate is commercially meaningful because the active ingredient cannot protect the product. Its strength depends on claim breadth, patent-term remaining, prosecution history, written-description support, prior art, and the ability to prove infringement through publicly observable product characteristics.

Strength factors

• A formulation that produces a distinctive release profile
• Claims supported by comparative pharmacokinetic data
• Multiple independent patent families
• Claims covering both composition and manufacturing
• Patents that remain listed in the Orange Book
• Limited design-around options

Weakness factors

• Heavy reliance on narrow polymer ratios
• Publicly detectable prior art involving oxcarbazepine extended release
• Claims limited to specific dissolution conditions
• Easy substitution of polymer grades or manufacturing steps
• Method-of-use claims vulnerable to label carving
• Patent terms approaching expiration

The most valuable patents are those that connect a specific excipient architecture with a measurable clinical or pharmacokinetic benefit. Generic applicants will often target the release profile and manufacturing process rather than the identity of the inactive ingredients alone.

What licensing opportunities exist around Oxtellar XR?

Licensing opportunities are strongest in four areas:

1. Generic development. A developer with an ANDA-ready extended-release platform could license a formulation, bioequivalence package, or manufacturing process to a generic sponsor.
2. Regional commercialization. Rights outside the United States may be available where Supernus has limited commercial reach or where local regulatory pathways differ.
3. Pediatric delivery. A sprinkle or multiparticulate product could support a separate license focused on pediatric adherence.
4. Excipient technology. A polymer platform that reduces food effect or improves release robustness could be licensed across multiple antiseizure products.

A licensing agreement would need to address Orange Book patents, regulatory exclusivity, manufacturing rights, technology-transfer obligations, pharmacovigilance, supply continuity, and responsibility for Paragraph IV litigation.

How does Oxtellar XR compare with immediate-release oxcarbazepine?

Attribute	Oxtellar XR	Immediate-release oxcarbazepine
Dosing	Once daily	Commonly twice daily
Active ingredient	Oxcarbazepine	Oxcarbazepine
Release	Extended	Immediate
Commercial position	Branded convenience and controlled exposure	Low-cost generic
Patent value	Formulation and method claims	Limited product-patent value
Generic competition	More technically complex	Mature and extensive
Main excipient opportunity	Release control	Manufacturability and cost
Main payer risk	Premium erosion	Commodity pricing

Oxtellar XR’s commercial defense is convenience and pharmacokinetic differentiation. Its vulnerability is payer substitution when the premium over immediate-release oxcarbazepine exceeds the perceived adherence or tolerability benefit.

What is the revenue exposure from generic entry?

Revenue exposure depends on the share of prescriptions that can be converted to immediate-release oxcarbazepine, the number of approved extended-release competitors, payer formulary rules, and the timing of any settlement-controlled launch.

The typical sequence is:

1. First Paragraph IV filing creates legal and investor risk.
2. Litigation may delay approval or launch.
3. A first generic entrant can receive substantial price erosion protection if eligible for 180-day exclusivity.
4. Additional entrants accelerate net-price decline.
5. Immediate-release substitution expands as payers revise formularies.
6. Branded revenue stabilizes around patients with adherence, tolerability, or physician-preference advantages.

The most defensible revenue segment is likely patients who benefit from once-daily dosing or cannot maintain control on an immediate-release schedule. The most exposed segment is price-sensitive maintenance therapy with no documented need for the branded extended-release formulation.

Key Takeaways

• Oxtellar XR is a once-daily extended-release oxcarbazepine tablet whose value comes from formulation performance, not active-ingredient exclusivity.
• Hypromellose, microcrystalline cellulose, crospovidone, and coating excipients support the product’s controlled-release tablet architecture.
• The highest-value excipient opportunities involve release robustness, reduced food effect, dose scaling, and pediatric administration.
• Regulatory exclusivity from the 2012 approval has expired; current entry risk is driven primarily by listed patents and litigation.
• A conventional ANDA is technically feasible but must manage dissolution, pharmacokinetic, food-effect, and formulation-equivalence risks.
• A differentiated 505(b)(2) product could target pediatric sprinkle delivery, multiparticulates, or improved tolerability.
• Immediate-release oxcarbazepine creates a permanent pricing threat because it provides a low-cost therapeutic alternative.
• Current Orange Book listings, Paragraph IV filings, litigation dockets, and settlement agreements control the precise generic-entry forecast.

FAQs

Can a generic replace Oxtellar XR with immediate-release oxcarbazepine?

Not automatically. The products differ in release characteristics and dosing frequency. A physician or pharmacist must determine whether conversion is clinically appropriate.

Is hypromellose the key patentable excipient in Oxtellar XR?

Not by itself. Patent value generally depends on the complete formulation architecture, polymer grade, concentration, release profile, manufacturing process, and resulting pharmacokinetic performance.

Could a competitor develop an Oxtellar XR sprinkle formulation?

Yes, but the competitor would need to preserve extended release after administration with soft food or liquid. That would likely require a new dosage-form development and regulatory strategy.

Does Oxtellar XR qualify for biologic or biosimilar exclusivity?

No. Oxtellar XR is a small-molecule oral drug, not a biologic. Biosimilar rules do not apply.

What is the best commercial strategy for an Oxtellar XR follow-on product?

A sponsor should compare three paths: a conventional ANDA, a non-infringing extended-release formulation, and a 505(b)(2) product with pediatric or administration advantages. The optimal route depends on patent scope, bioequivalence feasibility, manufacturing cost, and payer willingness to reward differentiation.

References

1. U.S. Food and Drug Administration. (2024). Oxtellar XR (oxcarbazepine) extended-release tablets: Prescribing information. Supernus Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2012). FDA approves Oxtellar XR for partial-onset seizures. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA Center for Drug Evaluation and Research.

4. Supernus Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

5. U.S. Food and Drug Administration. (2015). Guidance for industry: ANDAs for certain highly soluble, highly permeable drugs. Center for Drug Evaluation and Research.